Adherence to Inflammatory Bowel Disease Medications in Southern New Zealand

被引:9
|
作者
Aluzaite, Kristina [1 ]
Braund, Rhiannon [2 ]
Seeley, Liam [1 ]
Amiesimaka, Obreniokibo Ibifubara [1 ]
Schultz, Michael [1 ,3 ]
机构
[1] Univ Otago, Dept Med, Gastroenterol Res Unit, DSM, Dunedin, New Zealand
[2] Univ Otago, New Zealand Pharmacovigilance Ctr, Dunedin Sch Med, Dept Prevent & Social Med, Dunedin, New Zealand
[3] Southern Dist Hlth Board, Gastroenterol Unit, Dunedin Hosp, Dunedin, New Zealand
关键词
medication adherence; inflammatory bowel diseases; IBD; Otago; New Zealand; EVIDENCE-BASED CONSENSUS; ULCERATIVE-COLITIS; MAINTENANCE MEDICATION; INFLIXIMAB THERAPY; NONADHERENCE; IMPACT; MANAGEMENT; MEDICINES; DIAGNOSIS; KNOWLEDGE;
D O I
10.1093/crocol/otab056
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: Inflammatory bowel diseases (IBDs) require continuous clinical management; poor medication adherence may result in worse disease outcomes and increased healthcare costs. This study investigated medication adherence and associated risk factors in IBD patients. Methods: Otago (New Zealand) IBD patients were mailed questionnaires on demographics, medication-taking behavior, and a validated Probabilistic Medication Adherence Scale (ProMAS). Results: The response rate was 29.7% (n = 174/590). The study sample was mean (SD) 50.5 (16.9) years old, 57.9% female, 49.4% had Crohn's disease, and 43.9% ulcerative colitis, with median of 9.5 years (interquartile range: 5.0-22.0) of IBD duration. About 31.1% scored below medium adherence according to ProMAS. About 11.9%, 24.7%, and 23.1% reported failing to renew, purposely not taking, and stopping taking medications, respectively; 27.2% of those who reported having no issues taking medication scored below medium on the ProMAS. Older age was associated with higher ProMAS adherence score (Pearson's r = .25; P = .0014). There were no differences in medication adherence between the types of IBDs (P = .87), disease activity status (P =.70), or gender (P = .27). There was no correlation between the number of medications and level of adherence (Pearson's r = .09; P = .27). About 18.7%, 10.1%, and 5.0% of patients reported forgetting to take medications when traveling, when out of routine, and when busy, respectively. The most used strategies to remember medications included utilizing specific routines (40.1%) and keeping medications in specific locations (21.1%). Conclusions: A third of IBD patients had below medium medication adherence. There were discrepancies between self-reported and toolassessed medication adherence scores with over one-third of patients underestimating/overestimating their adherence. Lay Summary A third of Otago, New Zealand, IBD patients had below medium medication adherence, with adherence positively associated with age. There were discrepancies between self-reported and tool-assessed medication adherence scores with over one-third of patients underestimating or overestimating their adherence.
引用
收藏
页数:6
相关论文
共 50 条
  • [1] Patients' Perspectives on Inflammatory Bowel Disease Medication Adherence in Southern New Zealand
    Amiesimaka, O.
    Braund, R.
    Aluzaite, K.
    Schultz, M.
    [J]. INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2023, 45 (01)
  • [2] Medication adherence to inflammatory bowel disease medications in Aotearoa New Zealand and correlation with health outcomes: A nationwide database analysis
    Amiesimaka, Obreniokibo Ibifubara
    Allemann, Samuel S.
    Braund, Rhiannon
    Schultz, Michael
    Aluzaite, Kristina
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2024, 90 (08) : 1911 - 1920
  • [3] Paediatric inflammatory bowel disease in New Zealand
    Yap, Jason
    Wesley, Alison
    Mouat, Stephen
    Chin, Simon
    [J]. NEW ZEALAND MEDICAL JOURNAL, 2008, 121 (1283) : 19 - 34
  • [4] A call for collaboration on inflammatory bowel disease in New Zealand
    Walmsley, Russell
    [J]. NEW ZEALAND MEDICAL JOURNAL, 2012, 125 (1349) : 7 - 10
  • [5] Pregnancy and medications in inflammatory bowel disease
    Cao, Rena H.
    Grimm, Michael C.
    [J]. OBSTETRIC MEDICINE, 2021, 14 (01) : 4 - 11
  • [6] Hepatotoxicity of Inflammatory Bowel Disease Medications
    Shamberg, Lucy
    Vaziri, Haleh
    [J]. JOURNAL OF CLINICAL GASTROENTEROLOGY, 2018, 52 (08) : 674 - 684
  • [7] Attitudes and Adherence to Inflammatory Bowel Disease (IBD) Medications in a Racially and Ethnically Diverse Population
    Shah, Shamita
    Kabagambe, Edmond K.
    Shillington, Alicia
    Patel, Aarti A.
    Capelouto, Joseph A.
    Deering, Kathleen L.
    Elmayan, Ardem
    Babin, Sheena
    LaChappelle, Brandon
    Liu, Julia
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2022, 117 (10): : S702 - S702
  • [8] Prospective Incidence of Paediatric Inflammatory Bowel Disease in New Zealand in 2015: Results From the Paediatric Inflammatory Bowel Disease in New Zealand (PINZ) Study
    Lopez, Robert N.
    Evans, Helen M.
    Appleton, Laura
    Bishop, Jonathan
    Chin, Simon
    Mouat, Stephen
    Gearry, Richard B.
    Day, Andrew S.
    [J]. JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 2018, 66 (05): : E122 - E126
  • [9] Patients' accounts of living with and managing inflammatory bowel disease in rural Southern New Zealand: a qualitative study
    Richard, Lauralie
    Noller, Geoff
    Derrett, Sarah
    Sullivan, Trudy
    Doolan-Noble, Fiona
    McCombie, Andrew
    Schultz, Michael
    Ho, Christine
    Stokes, Tim
    [J]. BMJ OPEN, 2020, 10 (11):
  • [10] INFLAMMATORY BOWEL-DISEASE IN AUCKLAND, NEW-ZEALAND
    EASON, RJ
    LEE, SP
    TASMANJONES, C
    [J]. AUSTRALIAN AND NEW ZEALAND JOURNAL OF MEDICINE, 1982, 12 (02): : 125 - 131